The reasons for its absence from the US market are multifactorial: No FDA Application Filed: Ever Neuro Pharma, the Austrian manufacturer, has not pursued FDA approval
(1986) Dual effects of growth hormone (GH)-releasing hormone infusion in normal men: somatotroph desensitization and increase in releasable GH
So let's walk through this together, not just with formulas, but with the practical insights we've gathered over years of experience
Home kits often lack pharmaceutical-grade purity and precise clinical dosage control, significantly increasing the risk of adverse health effects.
Peter Attia, a longevity physician, discusses NAD+ precursors: "While evidence is emerging, NAD+ boosting shows promise for mitochondrial health and longevity, though IV might not be optimalprecursors like NMN could be better."[33][20] On combinations, he cautions on long-term data but notes potential for metabolic disorders